Takeda Pharmaceutical Company Ltd. (NYSE:TAK) reported fourth-quarter sales of $6.98 billion, or 1.094 trillion yen, missing Wall Street estimates of $7.05 billion.
The Japanese drugmaker reported adjusted earnings of 28 cents per ADR (89 yen per share), beating analyst estimates of 21 cents per share.
CFO Highlights Profitability, Cash Flow Focus
Chief Financial Officer Milano Furuta said the company delivered “solid profit and cash flow through disciplined cost control” in fiscal 2025 despite revenue headwinds, while continuing to invest in product launches and its pipeline.
“In FY2026, we will continue to focus on transforming operations and protecting profitability while delivering successful launches and advancing our pipeline. Strong cash flow generation and deleveraging will support long-term investment for growth acceleration and ensure competitive returns for our shareholders,” Furuta said.
Read Also: Takeda Exits Dementia Drug Partnership With Denali Therapeutics – Here’s Why
Late-Stage Pipeline Supports Takeda Growth Outlook
Takeda said its late-stage pipeline could support multiple regulatory approvals in the U.S. and other markets during fiscal 2026 and 2027.
The company is preparing for a U.S. launch of oveporexton, a potential first-in-class orexin agonist for narcolepsy type 1, after receiving Priority Review from the U.S. Food and Drug Administration.
View more earnings on TAK
Takeda is also planning a U.S. launch for rusfertide, a hepcidin mimetic candidate for polycythemia vera, following FDA Priority Review designation.
Meanwhile, zasocitinib, an oral psoriasis treatment candidate, is expected to move toward regulatory filing in 2026, with a commercial launch targeted for the first half of 2027.
Fiscal 2026 Outlook
Takeda forecast fiscal 2026 adjusted earnings of 31 cents per share, or 472 yen, and sales of $29.58 billion, or 4.64 trillion yen.
TAK Price Action: Takeda Pharmaceutical shares were up 0.24% at $16.47 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo via Shutterstock
Read Also: Anthony Scaramucci Says AI Could Drive 6%-7% US GDP Growth, Shrink Debt Burden Like Post-WWII Boom
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga:
This article Takeda's Next Wave of Drugs Has Investors Watching Closely originally appeared on Benzinga.com
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Disclaimer : This story is auto aggregated by a computer programme and has not been created or edited by DOWNTHENEWS. Publisher: finance.yahoo.com
